cibinqo
Eczema Treatments
cibinqo
Eczema Treatments

Cibinqo

Use Cibinqo® (abrocitinib) as prescribed to help treat moderate to severe eczema (atopic dermatitis) by targeting Janus kinase (JAK) pathways involved in inflammation and itch signaling.
Cibinqo is an oral Janus kinase (JAK) inhibitor that reduces inflammation and itching associated with eczema. It is effective for moderate to severe atopic dermatitis.
Cibinqo is prescribed for adults with moderate to severe eczema who have not responded to topical treatments or biologics.
Many patients experience relief from itching within days, with visible skin improvements within 2–4 weeks.
Cibinqo is prescribed for adults with moderate to severe eczema who have not responded adequately to topical therapies or when other systemic treatments are not appropriate. It is taken as an oral, once-daily medication under clinician supervision. See pricing details here.

Real patients, real results

How effective is Cibinqo

Clinically proven results

Rapid itch relief and skin improvement with meaningful reductions in eczema severity.*
The clinical results are in: Finasteride has been shown to be effective at preventing hair loss and even regrowing hair in some men.
*In clinical trials, many patients treated with Cibinqo experienced substantial itch reduction as early as Week 1 and improved eczema severity compared to placebo.
Cibinqo should be used only as prescribed. For more details, see Important Safety Information.

How DermOnDemand Works

Common Question

Side effects include nausea, headache, or increased susceptibility to infections.
Yes, it is often used alongside topical treatments or moisturizers for comprehensive eczema management.